Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s240, 2023. DOI: 10.25251/skin.7.supp.240. Disponível em: https://skin.dermsquared.com/skin/article/view/2359. Acesso em: 4 apr. 2025.